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A B S T R A C T   
Objectives: Emerging evidence has indicated a role for pharmacologic agents in the primary prevention of 
osteoporotic fracture, but have not yet been systematically reviewed for meta-analysis. We conducted a meta- 
analysis to evaluate the eficacy of pharmacologic interventions in reducing fracture risk and increasing bone 
mineral density (BMD) in postmenopausal women with osteopenia or osteoporosis but without prevalent fragility 
fracture. 
Method: The Medline, EMBASE, and CENTRAL databases were searched from inception to September 30, 2019. 
Only randomized placebo-controlled trials evaluating postmenopausal women with −1.0 > bone mineral density 
(BMD) T-score > −2.5 (low bone mass) and those with BMD T-score ≤ −2.5 (osteoporosis) but without baseline 
fractures, who were receiving anti-osteoporotic agents, providing quantitative outcomes data and evaluating risk 
of vertebral and/or non-vertebral fragility fracture at follow-up. The PRISMA guidelines were followed, applying 
a random-effects model. The primary endpoint was the effect of anti-osteoporotic regimens in reducing the 
incidence of vertebral fractures. Secondary endpoints were percentage changes in baseline BMD at the lumbar 
spine and total hip at 1 and 2 years follow up. 
Results: Full-text review of 144 articles yielded, 20 for meta-analysis. Bisphosphonates reduced the risk of 
vertebral fracture (pooled OR = 0.50, 95%CIs = 0.36–0.71) and signiicantly increased lumbar spine BMD after 
1 year, by 4.42% vs placebo (95%CIs = 3.70%–5.14%). At the hip, this value was 2.94% (95%CIs = 2.13%– 
3.75%). Overall results of limited studies for non-bisphosphonate drugs showed increased BMD and raloxifene 
signiicantly decreases the risk of subsequent clinical vertebral fractures. 
Conclusion: The bisphosphonates are eficacious and most evident for the primary prevention of osteoporotic 
vertebral fractures, reducing their incidence and improving BMD in postmenopausal women with osteopenia or 
osteoporosis.   
1. Introduction 
Fragility fractures commonly cause disabilities and mortality in older 
adults and are major contributors to medical care costs worldwide 
(Sanchez-Riera and Wilson, 2017). A majority of such fractures occur in 
postmenopausal women without osteoporosis diagnoses (Lindsay et al., 
2001), yet low bone mineral density (BMD) is recognized as an impor-
tant preventable risk factor for osteoporotic fractures (Sanchez-Riera 
and Wilson, 2017). Women who develop osteoporotic vertebral and hip 
fractures are at substantial risk for additional fractures within 1 year 
(Johansson et al., 2017). Consequently, preventing fragility fractures is 
of both clinical and public health importance. 
Annually, about three million individuals are diagnosed with oste-
oporosis in the United States (Eriksen, 2012). The U.S. Preventive Ser-
vices Task Force advises that all women aged more than 65 years should 
be screened for osteoporosis using dual-energy X-ray absorptiometry 
(DXA) (USPSTF et al., 2018), which reports results as T-scores based on 
the standard deviation of the mean BMD in the general population. The 
World Health Organization deines osteopenia (low bone mass) as a 
BMD T-score between −1 and − 2.5 at the hip or spine and osteoporosis 
as a T-score of −2.5 and below (World Health Organization, 2007). The 
majority of patients presenting with fractures have BMDs in the osteo-
penic range primarily because the osteopenic population is larger than 
the osteoporotic population (Eriksen, 2012; Kanis, 1994; Cranney et al., 
2007). Although an osteopenic T-score may not indicate a need for 
treatment, a high risk for future fractures as determined by risk calcu-
lators (e.g., FRAX (Siris et al., 2010)) can suggest therapy for osteopo-
rosis (Eriksen, 2012). Theoretically, the intervention for subjects have 
experienced fracture to prevent a recurrent fracture is considered as 
“secondary” prevention of osteoporotic fracture. On the contrary, the 
intervention for subjects with low bone mass or osteoporosis but without 
clinical fracture is usually called as “primary” prevention of fracture. 
The eficacies of various pharmacologic interventions for treating 
postmenopausal osteoporosis have been compared in many studies, 
including several noteworthy network meta-analyses (Barrionuevo 
et al., 2019; Liu et al., 2018; Wang et al., 2017; Yang et al., 2016a; Zhou 
et al., 2016). Results of such studies have led to a universal acceptance of 
pharmacologic treatment for osteoporosis with fragility fractures and 
recommendations by current guidelines (Qaseem et al., 2017). However, 
fewer studies have addressed the potential eficacy of pharmacologic 
intervention for the primary prevention of fragility fractures or bone loss 
in patients with increased risks of fracture due to low bone mass. 
Emerging evidence has indicated that pharmacologic agents for 
osteoporosis treatment, bisphosphonates most abundantly (Iqbal et al., 
2019; Grey et al., 2014; Quandt et al., 2005), can also effectively lower 
fracture risk and prevent bone loss in osteopenic women, as well as 
patients with T-scores in the osteoporotic range, even those without 
previous fractures. To date, however, the indings of these and other 
studies have not been systematically reviewed. Therefore, this review 
was performed to evaluate the eficacies of pharmacologic interventions 
on reducing fracture risk and improving BMD in postmenopausal 
women with osteopenia or osteoporosis but without prior fragility 
fractures. 
2. Materials and methods 
2.1. Search strategy 
This study was performed in accordance with PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. 
The Medline, EMBASE, and CENTRAL databases were searched from 
inception to September 30, 2019. The availability of the abstract and the 
publication language (English) were used as ilters in the searches of 
Medline and EMBASE. Reference lists of relevant studies were manually 
searched. The following keywords and word combinations were used:  
(osteoporosis OR osteopenia OR low bone mass) AND (alendronate OR alendronic acid 
OR risedronate OR risedronic acid OR ibandronate OR ibandronic acid OR 
pamidronate OR pamidronic acid OR zoledronate OR zoledronic acid OR 
bisphosphonate) 
(osteoporosis OR osteopenia OR low bone mass) AND (raloxifene OR bazedoxifene OR 
SERM OR selective estrogen receptor modulator) 
(osteoporosis OR osteopenia OR low bone mass) AND (tibolone OR STEAR OR 
selective tissue estrogenic activity regulator) 
(osteoporosis OR osteopenia OR low bone mass) AND calcitonin 
(osteoporosis OR osteopenia OR low bone mass) AND (teriparatide OR parathyroid 
hormone analog) 
(osteoporosis OR osteopenia OR low bone mass) AND (hormone replacement therapy 
OR estrogen) 
(osteoporosis OR osteopenia OR low bone mass) AND strontium ranelate 
(osteoporosis OR osteopenia OR low bone mass) AND denosumab OR RANKL inhibitor 
(osteoporosis OR osteopenia OR low bone mass) AND romosozumab  
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2.2. Selection criteria 
Inclusion criteria were: randomized placebo-controlled trial (RPCT); 
evaluation of postmenopausal women with low bone mass (or osteo-
penia or low bone density, deined as −1.0 > BMD T-score > −2.5, 
measured by DXA) and without baseline vertebral fractures and/or 
other fragility fractures or of those with osteoporosis (BMD T-score ≤
−2.5) and without baseline vertebral fractures and/or other fragility 
fractures; pharmacologic intervention for at least 1 year with 1) the 
nitrogen-containing bisphosphonates alendronate, zoledronate, ibandr-
onate, or risedronate, 2) a selective estrogen receptor modulator 
(SERM), 3) calcitonin, 4) teriparatide or a parathyroid hormone analog, 
5) strontium ranelate, 6) denosumab, 7) estrogen, 8) tibolone, or 9) 
romosozumab. Studies were also required to have quantitative outcome 
data evaluating the risk of vertebral and/or non-vertebral fragility 
fracture at follow-up and/or BMD measures for the lumbar spine or total 
hip. Cohort studies, letters, comments, reviews, editorials, case reports, 
proceedings, personal communications, and retrospective studies were 
excluded. Patients with vertebral fractures at baseline; histories of 
lumbar spine surgeries; cancer, renal insuficiency, or severe cardio-
vascular conditions; bone metabolic disease other than osteoporosis, or 
any illness known to affect bone metabolism (e.g., Paget’s disease or 
hyperparathyroidism); chronic treatment with drugs affecting bone 
metabolism (eg, glucocorticoids); combination regimens (more than 1 
drug) of these drugs; and studies not designed for irst-time pharmaco-
logic intervention (ie, inclusion of patients with prior drug therapies) 
were also excluded. 
Studies were identiied by 2 independent reviewers, experienced in 
osteoporosis management, using the above search strategy. When 
eligibility was uncertain, a third reviewer was consulted. 
2.3. Data extraction 
Data extracted from those studies meeting selection criteria were: 
name of irst author; year of publication; study design; participant group 
sizes; DXA sites and BMD T-score ranges; treatment protocol (drug, dose, 
duration, frequency, and route of administration); mean values for 
participant age, time since menopause, and baseline BMD at the lumbar 
spine, total hip, and femoral neck; levels of calcium and/or vitamin D 
supplementation; and outcomes of interest (Table 1 details the inde-
pendent variables). For trials using various dosages of a single drug, the 
dosages most similar to other trials were selected to minimize con-
founding. Various pharmacologic regimens were used, depending on 
drug: alendronate (70 mg once weekly or 10 mg once daily), zoledronate 
(5 mg IV infusion), ibandronate (5 mg once daily or 20 mg once weekly 
or 150 mg once monthly), risedronate (5 mg once daily), teriparatide 
(20 μg once daily), raloxifene (60 mg daily), denosumab (60 mg every 6 
months), or romosozumab (210 mg monthly). 
2.4. Ethics statement 
The protocol for this review and meta-analysis was reviewed and 
approved by the Internal Review Board of National Cheng Kung Uni-
versity Hospital (A-EX-108-051). Raw patient data and private infor-
mation were neither required nor used; therefore, informed consent was 
unnecessary. 
2.5. Quality assessment 
The Cochrane Collaboration tool (Higgins et al., 2011) was used to 
assess included studies for risk of bias via seven criteria: selection bias 
(random sequence generation; allocation concealment), performance 
bias (blinding of participants and personnel), detection bias (blinding of 
outcome assessment), attrition bias (incomplete outcome), reporting 
bias (selective outcome reporting), and inclusion of intention-to-treat 
analysis. Quality assessment was performed by 2 independent 
reviewers, consulting a third reviewer in the case of uncertainty. 
2.6. Outcome measures 
The primary endpoint for this meta-analysis was the effect of 
bisphosphonates in reducing the incidence of vertebral fractures. Sec-
ondary endpoints were percentage changes between the baseline BMD 
at the lumbar spine and/or total hip and after 1 and 2 years of follow-up. 
Fracture risk reduction was measured as the difference between the 
treated and placebo groups in the incidence of vertebral fractures during 
follow-up and improvement in BMD at the lumbar spine and total hip as 
measured by the mean percentage change between baseline values and 
those at 1 and/or 2 years of follow-up. 
2.7. Statistical analysis 
A χ2-based test of homogeneity was performed using Cochrane’s Q 
statistic and I2, the percentage of total variability in effect estimates 
among included trials that results from heterogeneity rather than 
chance. A random-effects model was also applied. Odds ratios (ORs) 
were calculated for the primary endpoint using 2 × 2 tables, and addi-
tional ORs (with corresponding 95% conidence intervals [CIs]) were 
calculated for combined studies. Differences in means (with corre-
sponding 95% CIs) were calculated for the secondary endpoints for each 
individual study and for combined studies. Pooled effects were calcu-
lated, and a 2-tailed P value < 0.05 was established for statistical sig-
niicance. Subgroup analyses of treatment effects were performed for 
each speciic bisphosphonate (zoledronate, alendronate, ibandronate, 
and risedronate) when the BMD T-score indicated osteopenia. 
A sensitivity analysis was carried out using the leave-one-out 
approach. Publication bias was evaluated using funnel plots (Sterne 
et al., 2011) assessed by applying the Egger’s test for asymmetry. The 
absence of publication bias was found when the data points formed a 
symmetric funnel-shaped distribution, and the one-tailed signiicance 
level was P > 0.05. All analyses were performed using Comprehensive 
Meta-Analysis statistical software, version 2.0 (Biostat, Englewood, NJ, 
USA). 
3. Results 
3.1. Search results 
The PRISMA low diagram for study selection is shown in Supple-
mental Fig. 1. Of 144 articles identiied for full-text review, 124 were 
excluded, and the 20 meeting inclusion criteria were included this study 
(Grey et al., 2014; Quandt et al., 2005; Ascott-Evans et al., 2003; Binkley 
et al., 2014; Bock et al., 2012; Bone et al., 2008; Cummings et al., 1998; 
Downs Jr. et al., 2000; Grey et al., 2009; Ishibashi et al., 2017; Kanis 
et al., 2003; McClung et al., 2006; McClung et al., 2009; McClung et al., 
2014; Naylor et al., 2016; Ravn et al., 1996; Reid et al., 2002; Siris et al., 
2008; Yang et al., 2016b; Yen et al., 2000). Of those, 14 focused on the 
effects of bisphosphonates and were included in the meta-analysis 
(quantitative analysis), and 9 focused on non-bisphosphonate drugs 
(Binkley et al., 2014; Bone et al., 2008; Downs Jr. et al., 2000; Ishibashi 
et al., 2017; Kanis et al., 2003; McClung et al., 2006; Naylor et al., 2016; 
Yang et al., 2016b) and were evaluated qualitatively only (3 RPCTs 
(Downs Jr. et al., 2000; McClung et al., 2006; McClung et al., 2014) 
evaluated bisphosphonates and non-bisphosphonate drugs; results were 
included in both the meta-analysis and the qualitative evaluation). 
3.2. Study characteristics 
The primary characteristics of those studies included in the meta- 
analysis are summarized in Table 1. In total, the 14 studies reported 
results for 8813 postmenopausal women, 4500 receiving bisphospho-
nates and 4313 receiving placebo, who met the criteria for low bone 
C.-H. Wu et al.                                                                                                                                                                                                                                  
BoneReports13(2020)100729
4
Table 1 
Characteristics of studies included in the meta-analysis.  
First author 
(year) 
Osteopenia/ 
osteoporosis 
Therapeutic 
drug 
Time since 
menopause, y 
n. of 
pts 
Treatment protocol Age, 
y 
Baseline BMD Combined treatment 
Lumbar spine Total hip Femoral neck 
Dose Duration, frequency Route of 
administration 
g/ 
cm2 
T- 
score 
g/ 
cm2 
T- 
score 
g/ 
cm2 
T- 
score 
Calcium, 
mg/d 
Vitamin 
D, IU/d 
Zoledronate vs placebo 
Grey (2014) Osteopenia Zoledronate n/a  43 5 mg Single administration i.v.  66 1.05 −1.1 0.84 −1.3 n/a n/a n/a n/a 
placebo  43   65 1.03 −1.3 0.87 −1.1 n/a n/a 
Grey (2009) Osteopenia Zoledronate n/a  25 5 mg Single administration i.v.  62 1.06 −1.0 0.85 −1.3 n/a n/a n/a n/a 
placebo  25   65 1.03 −1.3 0.86 −1.2 n/a n/a 
McClung 
(2009) 
Osteopenia Zoledronate 11.5  198 5 mg Single administration i.v.  59.6 0.86 −1.69 0.82 n/a 0.69 −1.40 500–1200 400–800 
placebo 11.4  202   60.5 0.86 −1.71 0.82 n/a 0.69 −1.47 
Reid (2002) Mixed Zoledronate n/a  53 4 mg Single administration i.v.  65 0.73 n/a n/a n/a 0.74 n/a 1000 n/a 
placebo  57   64 0.74 n/a n/a n/a 0.71 n/a  
Alendronate vs placebo 
McClung 
(2014) 
Mixed Alendronate n/a  47 70 
mg 
Once weekly for 1 year 
either monthly or every 3 
months for 1 year 
Oral  67.1 n/a −2.08 n/a −1.55 n/a −1.91 1000 800 
Placebo  47  s.c.  67 n/a −2.29 n/a −1.35 n/a −1.76 
McClung 
(2006) 
Mixed Alendronate 13.7  46 70 
mg 
Once weekly for 1 year Oral  62.8 n/a −2.0 n/a −1.6 n/a −1.9 n/a n/a 
placebo 13.8  46  Oral  63.7 n/a −2.2 n/a −1.4 n/a −1.9 n/a n/a 
Quandt 
(2005) 
Osteopenia Alendronate 20.2  1394 5 mg daily for the irst 2 years then 
10 mg daily 
Oral  66.9 0.87 n/a 0.75 n/a n/a n/a 500 250 
Placebo 20.4  1403  67 0.88 n/a 0.74 n/a n/a n/a 
Ascott-Evans 
(2003) 
Mixed Alendronate 11.4  95 10 
mg 
Once daily for 1 year Oral  57.3 −2.30 n/a n/a n/a n/a n/a 500 n/a 
Placebo 11.6  49   57.3 −2.22 n/a n/a n/a n/a n/a 
Downs 
(2000) 
Mixed Alendronate 16.5  118 10 
mg 
Once daily for 1 year Oral  64.6 n/a −2.54 n/a n/a n/a −2.63 500 400 
Placebo 16.5  58  Oral  64.6 n/a −2.36 n/a n/a n/a −2.59 
Yen (2000) Mixed Alendronate 11.7  24 10 
mg 
Once daily for 1 year Oral  59 0.72 −1.9    −1.9 500 n/a 
Placebo 11.8  22   60.3 0.72 −1.9    −1.6 
Cummings 
(1998) 
Mixed Alendronate n/a  2214 5 mg daily for the irst 2 years then 
10 mg daily 
Oral  67.6 0.841 n/a n/a n/a 0.592 n/a 500 250 
Placebo  2218  67.7 0.842 n/a n/a n/a 0.593 n/a  
Ibandronate vs placebo 
Bock (2011) Mixed Ibandronate 19.3  35 150 
mg 
Once monthly for 1 year Oral  69.3 0.76 −2.6 0.82 −1.0 n/a n/a 500 400 
Placebo 19.1  33   68.6 0.77 −2.5 0.84 −0.9 n/a n/a 
Ravn (1996) Mixed Ibandronate n/a  18 5.0 
mg 
Once daily for 1 year Oral  64.4 0.861 n/a n/a n/a 0.665 n/a 1000 n/a 
Placebo  25   64.4 0.826 n/a n/a n/a 0.653 n/a  
Risedronate vs placebo 
Siris (2008) Osteopenia Risedronate n/a  311 5 mg Once daily for 1.5 to 3 
years 
Oral  64 n/a n/a n/a n/a n/a −1.85 1000 500 
Placebo  309   64 n/a n/a n/a n/a n/a −1.84 
Abbreviations: i.v., intravenous infusion; s.c., subcutaneous injection; n/a, not available. 
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Table 2 
Characteristics of the studies on non-bisphosphonate drugs.  
First author 
(year) 
Osteopenia/ 
osteoporosis 
Therapeutic 
drug 
Time since 
menopause, y 
No. of 
pts 
Treatment protocol Age, 
y 
Baseline BMD Combined treatment 
Lumbar spine Total hip Femoral neck 
Dose Duration, frequency Route of 
administration 
g/ 
cm2 
T- 
score 
g/ 
cm2 
T- 
score 
g/ 
cm2 
T- 
score 
Calcium, 
mg/d 
Vitamin D, 
IU/d 
Ishibashi 
(2017) 
Osteoporosis Romosozumab n/a  59 210 
mg 
Once monthly for 1 
year 
s.c.  68.3 n/a −2.72 n/a −1.95 n/a −2.32  ≥500 ≥600 
Placebo  59   67.8 n/a −2.69 n/a −2.00 n/a −2.31 
Naylor 
(2016) 
Osteopenia Raloxifene n/a  21 60 
mg 
Once daily for 1 year Oral  63 0.857 n/a n/a n/a n/a n/a  500 n/a 
control (no 
treatment)  
23   61 0.903 n/a n/a n/a 
Yang 
(2016) 
Osteopenia Teriparatide 14.5  20 μg Once daily for 1 year s.c.  64.3 1.003 n/a 0.902 n/a 0.805   1000 400 
Placebo 13.6   Oral  63.9 1.01 n/a 0.906 n/a 0.801  
Binkley 
(2014) 
Osteopenia Calcitonin ≥5  78 0.2 
mg 
Once daily for 1 year Oral  67.5 n/a −1.15 n/a −1.23 n/a −1.69  600 1000 
Placebo  36   66.6 n/a −1.12 −1.20 n/a −1.73 
McClung 
(2014) 
Mixed Teriparatide n/a  46 20 μg Once daily for 1 year s.c.  66.8 n/a −2.29 n/a −1.32 n/a −1.79  1000 800 
Romosozumab  49 210 
mg 
Once monthly for 1 
year  
66.3 n/a −2.33 n/a −1.45 n/a −1.87 
Placebo  47  Either monthly or 
every 3 months for 1 
year  
67 n/a −2.29 n/a −1.35 n/a −1.76 
Bone 
(2008) 
Osteopenia Denosumab 10.5  166 60 
mg 
Every 6 months for 2 
years (at months 6, 
12, and 18) 
s.c.  59.8 n/a −1.55 n/a n/a n/a n/a  1000 400–800 
Placebo 9.4  166  oral  58.9 n/a −1.66 n/a n/a n/a n/a 
McClung 
(2006) 
Mixed Denosumab 15.7  46 60 
mg  
Oral  n/a −2.2 n/a −1.4 n/a −1.9  1000 400 
Placebo 13.8  46    63.7 n/a −2.2 n/a −1.4 n/a −1.9 
Kanis 
(2003) 
Osteopenia Raloxifene n/a  1287 60 
mg 
Once daily for 3 years Oral  65.2 0.85 −2.28 0.75 −1.71 0.63 −2.12  500 400–600 
Placebo  1270  
Osteoporosis Raloxifene  285 60 
mg 
Once daily for 3 years Oral  66.2 0.76 −3.07 0.61 −2.86 0.63 −2.85 
placebo  350  
Downs 
(2000) 
Mixed Calcitonin 16.1  123 200 
IU 
Once daily for 1 year Intra-nasal  64.1 n/a −2.54 n/a n/a n/a −2.71  500 400 
Placebo 16.5  58  Oral  64.6 n/a −2.36 n/a n/a n/a −2.59 
Abbreviations: s.c., subcutaneous injection; n/a, not applicable. 
C.-H. W
u et al.                                                                                                                                                                                                                                  
Bone Reports 13 (2020) 100729
6
mass based on BMD T-scores and lacked baseline vertebral fractures. In 
total, 319 women were treated with zoledronate, 3938 with alendro-
nate, 153 with ibandronate, and 311 with risedronate. Mean participant 
age ranged from 57.3 to 69.3 years. Study characteristics for those 
focusing on non-bisphosphonate pharmacologic agents are shown in 
Table 2. 
3.3. Meta-analyses 
3.3.1. Vertebral fractures 
Only 3 studies (Quandt et al., 2005; Cummings et al., 1998; Siris 
et al., 2008) providing data about vertebral fractures were included in 
the meta-analysis. Fig. 1 shows the forest plot indicating the effect of 
bisphosphonates on reducing vertebral fractures in postmenopausal 
women. Heterogeneity was not found between these 3 studies (Q = 1.96; 
I2 = 0.00%, P = 0.375). Results of the meta-analysis showed that 
bisphosphonates reduce the risk of subsequent vertebral fracture by 50% 
(pooled OR, 0.50; 95% CI, 0.36–0.71; P < 0.001). From the Fig. 1, the 
experimental event rate (EER) is 0.014, the control event rate (CER) is 
0.028, the absolute risk reduction (ARR) is 0.014 and NNT (number- 
needed to treat) is 71. That is, 71 patients would have to receive 
bisphosphonate treatment (instead of placebo) for one additional pa-
tient to not have vertebral fracture. 
3.3.2. Bone mineral density at the lumbar spine and total hip after 1 year of 
follow-up 
Twelve studies provided adequate data about the percentage change 
in BMD at the lumbar spine between baseline and 12 months of follow- 
up. Fig. 2A shows how the change in BMD at the lumbar spine differed 
between the bisphosphonate and placebo groups. Signiicant heteroge-
neity was found among the 12 studies (Q = 199.87; I2 = 94.50%, P <
0.001). Results show that bisphosphonates signiicantly increased lum-
bar spine BMD after 1 year, and the difference in mean BMD change 
versus placebo was 4.42% (95% CI, 3.70%–5.14%). 
Seven studies (Grey et al., 2014; Bock et al., 2012; Cummings et al., 
1998; Grey et al., 2009; McClung et al., 2006; McClung et al., 2009; 
McClung et al., 2014) provided adequate data about the percentage 
change in BMD in the total hip between baseline and 1 year of follow-up. 
Fig. 2B shows how the change in BMD in the total hip differed between 
the bisphosphonate and placebo groups. Signiicant heterogeneity was 
found among the 7 studies (Q = 94.16; I2 = 93.63%, P < 0.001). Results 
show a 2.94% difference in BMD changes between the bisphosphonate 
and placebo groups (95% CI, 2.13%–3.75%; P < 0.001). 
3.3.3. Bone mineral density at the lumbar spine and total hip after 2 years 
of follow-up 
Only 4 studies (Grey et al., 2014; Cummings et al., 1998; Grey et al., 
2009; McClung et al., 2009) provided adequate data about the per-
centage change in BMD at the lumbar spine or total hip after 2 years of 
follow-up. Results show that after 2 years, the bisphosphonate groups 
had greater increases in BMD at the lumbar spine and total hip, besting 
the placebo groups by 5.22% (95% CI, 4.79%–5.66%; P < 0.001; 
Fig. 2C) and 3.75% (95% CI, 3.16%–4.34%; P < 0.001; Fig. 2D), 
respectively. 
3.4. Sensitivity analysis and publication bias 
A sensitivity analysis was performed using the leave-one-out 
approach (ie, meta-analysis was repeated, removing each study in 
turn). Results are shown in Supplemental Table 1. The direction and 
magnitude of the combined estimates did not vary markedly with the 
removal of any given study, indicating good reliability in the meta- 
analysis and that the result was not overly inluenced by any individ-
ual study. 
The Egger’s test showed that publication bias was not present in the 
BMD results at the lumbar spine after 1 year of follow-up (t = 1.179, P =
0.133; Supplemental Fig. 1). 
3.5. Subgroup analysis 
Table 3 shows the results of subgroup analyses exploring the treat-
ment effectiveness of each individual bisphosphonate drug. Zoledro-
nate, after 1 year, increased BMD more than placebo by 3.74% at the 
lumbar spine and 3.15% in the total hip. Results were similar after 1 year 
of treatment with alendronate (5.18% and 3.09%, respectively) and 
after treatment with ibandronate (3.26% and 1.44%, respectively). 
After 2 years of treatment, zoledronate increased BMD more than 
placebo by 5.65% and 4.04% at the lumbar spine and in the total hip, 
respectively. 
When baseline BMD T-scores indicated osteopenia (−1 > T-score >
−2.5), bisphosphonates led to signiicantly greater increases in BMD 
after 1 and 2 years compared to placebo at both locations. 
3.6. Non-bisphosphonate drugs 
A qualitative review of non-bisphosphonate drugs was performed 
using the 9 studies of post-menopausal women (mean age, 58.9 to 68.3 
years) that met inclusion criteria (see Table 2). Three studies (Downs Jr. 
et al., 2000; McClung et al., 2006; McClung et al., 2014) included both 
bisphosphonate and non-bisphosphonate drugs and subsequently 
appear in both Tables 1 and 2. Overall, the non-bisphosphonate drugs 
were promising for increasing BMD in postmenopausal women with low 
bone mass at baseline. 
3.6.1. Denosumab 
After 12 months’ intervention, BMD signiicantly increased at the 
lumbar spine (3.0%–6.7%) and the total hip (1.9%–3.6%) compared to 
placebo (−0.8% and −0.6%, respectively) in postmenopausal women 
Fig. 1. Meta-analysis of the effect of bisphosphonate on reducing vertebral fractures in postmenopausal women with osteopenia/osteoporosis.  
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Fig. 2. Bone mineral density differences between bisphosphonate and placebo groups. Differences after 1 year of follow up at A, the lumbar spine and B, the total hip. 
Differences after 2 years of follow up at C, the lumbar spine and D, the total hip. 
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with low bone densities (McClung et al., 2006). Given biannually, 
denosumab signiicantly increased BMD at the lumbar spine compared 
to placebo (6.5% vs −0.6%) in women with lumbar spine BMD T-scores 
between −1.0 and −2.5 (Bone et al., 2008). 
3.6.2. Romosozumab 
After 12 months’ treatment, BMD signiicant increased in Japanese 
postmenopausal women compared to placebo (Ishibashi et al., 2017). At 
all dosages, romosozumab signiicantly increased BMD compared to 
placebo. At the lumbar spine and after 12 months of treatment, the 210- 
mg monthly dose increased BMD 11.3% compared to −0.1% with pla-
cebo in postmenopausal women with low bone density (McClung et al., 
2014). 
3.6.3. Raloxifene 
At week 48, the change in spine BMD was signiicantly different in 
the treatment group (0.031 g/cm2) compared to the no-treatment group 
(2.0% vs −1.1%) in postmenopausal osteopenic women (Naylor et al., 
2016). In 3204 osteopenic and osteoporotic women without vertebral 
fractures at baseline, the 60-mg daily dose signiicantly decreased the 
risk of subsequent clinical vertebral fractures compared to the placebo 
group (relative fracture risk, 0.25) (Kanis et al., 2003). 
3.6.4. Teriparatide 
A 20-μg daily subcutaneous dose resulted in increased BMD at the 
lumbar spine compared to placebo (7.1% vs −0.1%) after 12 months of 
treatment (McClung et al., 2014). This regimen also resulted in mean 
changes in BMD of 3.51%, 2.10%, and 1.80% at the lumbar spine, total 
hip, and femoral neck, respectively, in postmenopausal osteopenic 
women (Yang et al., 2016b). 
3.6.5. Calcitonin 
Treatment-naïve postmenopausal women with low bone densities 
and who received oral salmon calcitonin once daily for 1 year showed 
signiicant increases between baseline BMD and 24- and 58-week 
follow-ups (0.96% and 1.03%, respectively). Compared to placebo, 
these differences are signiicant (Binkley et al., 2014). Intranasal calci-
tonin therapy in osteoporotic postmenopausal women without prevalent 
vertebral fractures, changes in BMD at the femoral neck were greater 
than those with placebo, but this was not true for the lumbar spine BMD 
at 12 months (Downs Jr. et al., 2000). 
3.7. Quality assessment 
Results of the quality assessment for the included studies are shown 
in Supplemental Fig. 2. The summary of assessment indicated that the 
included studies could have a slight risk for bias and fair application 
concerns (Supplemental Fig. 2A) but all demonstrated adequate quality 
(Supplemental Fig. 2B). 
4. Discussion 
Results of this meta-analysis show that nitrogen-containing 
bisphosphonates are eficacious in the primary prevention of vertebral 
fracture in postmenopausal women with osteopenia or osteoporosis, 
reducing the risk of fracture by approximately 50%. Nitrogen-containing 
bisphosphonates are also eficacious in improving BMD at the lumbar 
spine or total hip after 1 to 2 years of follow-up, even in osteopenic 
patients. The speciic bisphosphonate drugs, zoledronate, alendronate, 
and ibandronate, each showed signiicant beneits in improving BMD. 
The evidence gathered during this qualitative review indicate that the 
non-bisphosphonate agents denosumab, romosozumab, raloxifene, ter-
iparatide, and calcitonin are also eficacious in primary prevention, but 
meta-analysis was not possible with the small number of studies. 
Our results are comparable to those of a number of RPCTs, yet this 
work was more comprehensive and clearly deined than some other 
studies. To date, only 1 other systematic review shared our goal and 
focused on the use of bisphosphonates in osteopenia rather than 
exploring osteoporosis (Iqbal et al., 2019). However, meta-analyses 
were not performed in that study, and baseline fragility fractures were 
not ruled out, as in this study. A recent double-blind RPCT that inves-
tigated 2000 osteopenic women who received various doses of infusions 
of the most potent bisphosphonate, zoledronate (zoledronic acid), 
showed that vertebral and nonvertebral fragility fractures were signii-
cantly lower at 6-year follow-up (Reid et al., 2018). Those authors 
found, as we did, that bisphosphonates clearly reduce fracture risk and 
result in an incremental improvement in BMD in those with osteopenia. 
However, in that trial, women with pre-existing fractures were not 
excluded (nonvertebral fractures were seen in 24% of the participants at 
screening). The authors noted that, on the basis of their sub-analyses, 
when excluding the women with BMD T-scores less than −2, those 
with baseline risks of hip fracture exceeding 3%, those with baseline 
risks of major osteoporotic fracture exceeding 20% according to FRAX, 
and those with histories of nonvertebral fracture after 45 years old, 
zoledronate reduced total fragility fractures by 40% and non-vertebral 
fragility fractures by 43% (Reid et al., 2018). 
Unfortunately, because the data were insuficient, the summary ef-
fects for the eficacy of bisphosphonates on non-vertebral fractures 
could not be determined. Nevertheless, some included studies reported 
Table 3 
Summary effects of bisphosphonates versus placebo on BMD by subgroup.   
Number of 
studies 
Q 
statistic 
I2 Pooled 
effect size 
with 95% CI 
P value 
Lumbar spine — 1 year 
All women      
Zoledronate vs 
placebo  
4 13.68 78%  3.74  <0.001 
Alendronate vs 
placebo  
6 163.61 97%  5.18  <0.001 
Ibandronate vs 
placebo  
2 2.68 63%  3.26  <0.001 
Osteopenia subgroup      
Bisphosphonate vs 
placebo  
3 2.76 70%  3.48  <0.001  
Total hip — 1 year 
All women      
Zoledronate vs 
placebo  
3 4.54 56%  3.15  <0.001 
Alendronate vs 
placebo  
3 62.55 97%  3.09  0.001 
Ibandronate vs 
placebo  
1 NA n/a  1.44  0.015 
Osteopenia subgroup      
Bisphosphonate vs 
placebo  
3 4.54 56%  3.15  <0.001  
Lumbar spine — 2 year 
All women      
Zoledronate vs 
placebo  
3 0.28 0%  5.65  <0.001 
Alendronate vs 
placebo  
1 NA n/a  5  <0.001 
Osteopenia subgroup      
Bisphosphonate vs 
placebo  
3 0.28 0%  5.65  <0.001  
Total hip — 2 year 
All women      
Zoledronate vs 
placebo  
3 2.71 26%  4.04  <0.001 
Alendronate vs 
placebo  
1 NA n/a  3.3  0.001 
Osteopenia subgroup      
Bisphosphonate vs 
placebo  
3 2.71 26%  4.04  <0.001 
Abbreviations: BMD, bone mineral density; CI, conidence interval; n/a, not 
applicable. 
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the incidence of non-vertebral fractures between treatment and placebo 
groups and included any decreased risk of non-vertebral fractures 
(relative hazard, 0.88) after 4 years of alendronate therapy versus pla-
cebo (Cummings et al., 1998). Additionally, a signiicant reduction in 
the risk for non-vertebral fractures (relative hazard, 0.09) was found 
when comparing 3 years of risedronate therapy with placebo across over 
600 women with osteopenia (Siris et al., 2008). 
In most of the included studies, changes in BMD between baseline 
and follow-up were evaluated at 1 or 2 years. However, extended follow- 
up results were sometimes reported, offering additional insight. In the 
Fracture Intervention Trial, Cummings et al. (Cummings et al., 1998) 
tested the hypothesis that 4 years of alendronate therapy would decrease 
fracture risks in women with low bone densities but without vertebral 
fractures; the inding was that BMD was safely increased across 4 
consecutive years, and the risk of a irst vertebral deformity also was 
decreased. This study followed another by the same authors which 
showed that alendronate decreased the risks of vertebral, hip, and wrist 
fractures by 50% and clinical fractures by 28% in women with prior 
vertebral fractures. McNabb et al. (McNabb et al., 2013) studied patterns 
of change in BMD to determine whether rates of BMD loss changed after 
discontinuing bisphosphonate therapy for 3 to 5 years. Results showed 
that one-third of women who discontinued bisphosphonate therapy had 
more than 5% bone loss in the total hip after 5 years; age and body mass 
index were risk factors for greater bone loss after drug discontinuance. 
Grey et al. (Grey et al., 2017) extended their 2-year RPCT by an addi-
tional 3 years (Grey et al., 2009) to achieve 5 years of total therapy and 
explore the duration of antiresorptive activity of zoledronate in post-
menopausal women with osteopenia. Results showed that a single dose 
of zoledronate produced a persistent antiresorptive effect (Grey et al., 
2017). 
Though pooled estimates for non-bisphosphonates was not possible 
in our work, we qualitatively reviewed the studies and found that non- 
bisphosphonate agents might also be effective in the primary prevention 
of fragility fractures. Kanis et al. (Kanis et al., 2003) showed that ral-
oxifene signiicantly decreased the risk of subsequent clinical vertebral 
fractures in osteopenic or osteoporotic women without prior vertebral 
fractures. Compared to the no-treatment group, the treatment group 
showed a signiicant change in spine BMD at week 48 in postmenopausal 
osteopenic women (Naylor et al., 2016). We found that after 12 months 
of denosumab, BMD increased 3.0% to 6.7% at the lumbar spine and 
1.9% to 3.6% in the total hip (McClung et al., 2006). Also, twice-yearly 
injectable denosumab increased BMD at the lumbar spine (Bone et al., 
2008). Recent studies compared bisphosphonates with various agents in 
osteoporotic women with/without prior fragility fractures (Lyu et al., 
2019; Wu et al., 2018). Lyu et al. (Eriksen, 2012) found that denosumab 
increased BMD more than bisphosphonates at the lumbar spine, total 
hip, and femoral neck at 12 and 24 months, leading to a lower incidence 
of osteoporotic fractures at 24 months (overall meta-analysis, not 
limited to patients with osteopenia). Another meta-analysis evaluating 
denosumab vs bisphosphonates showed that denosumab, but not 
bisphosphonates, signiicantly increased BMD at the lumbar spine, total 
hip, and femoral neck in postmenopausal osteoporosis patients (Wu 
et al., 2018). In an indirect comparison of denosumab, teriparatide, and 
oral bisphosphonates, Zhang et al. (2015) demonstrated that teripara-
tide and denosumab were more effective than alendronate and risedr-
onate in reducing vertebral fractures in osteoporotic women. Clearly, 
future studies for evaluating whether these drugs are more eficacious 
than bisphosphonates for the primary prevention for fractures among 
women with low bone densities are warranted. 
Our review showed that mean differences in BMD change ranged 
from 5% to 6% between the treatment and placebo groups. In a recent 
meta-regression of 38 placebo-controlled trials of 19 therapeutic agents, 
Bouxsein (Bouxsein et al., 2019) concluded that a 2% to 6% improve-
ment in total hip BMD implies a 28% to 66% reduction in risk for 
vertebral fracture. Changes in BMD noted in individual-level patient 
data from the FNIH Bone Quality Project supports this ratio between 
BMD improvement and fracture risk reduction (Black and Eastell, 2018). 
Post-treatment changes in BMD at 12 or 24 months, especially in the hip, 
serve as the most important surrogate endpoints for evaluating vertebral 
and hip fracture risk reduction and therapeutic response (Bouxsein et al., 
2019; Black and Eastell, 2018). Even small increases in BMD after 
treatment can be associated with a considerable reduction in subsequent 
fracture risk and could translate into clinically important fracture dif-
ferences when observed in large populations. Accordingly, our post- 
treatment BMD results are clinically relevant. 
4.1. Strengths and limitations 
This meta-analysis evaluated the eficacy of pharmacological inter-
vention for the primary prevention of fragility fractures in patients with 
osteopenia. Importantly, the inclusion and exclusion criteria were 
rigorously established, and the outcomes were carefully deined. 
Furthermore, all included studies were RPCTs of high quality. Pooled 
estimates of ORs were generally without high CIs, suggesting satisfac-
tory accuracy and reliability of the indings. Subgroup analyses were 
also conducted to identify potential bias, and a sensitivity analysis 
revealed the robustness of the primary results. 
Nevertheless, this review and meta-analysis has several limitations. 
The summary effects for non-vertebral fractures, total hip BMDs, and 
femoral neck BMDs could not be obtained due to lack of data. Because 
the presence of prior fragility fractures in many studies depended on 
self-reported medical histories, those with subclinical fragility fractures 
might have been erroneously included. Therefore, only those studies 
with clear descriptions of prior fragility fractures or spinal radiography 
were enrolled. The number of studies that analyzed vertebral fracture 
was also limited, though heterogeneity was low. The analysis of non- 
bisphosphonate drugs was performed as a qualitative review only. 
Treatment duration, changes in bone markers, and adverse events from 
pharmacologic interventions could not be assessed due to insuficient 
data across studies. Future studies must include comparative eficacy 
analyses and cost-effectiveness analyses of various pharmacologic in-
terventions for the primary prevention of osteoporotic fracture. 
5. Conclusions 
Of all the anti-osteoporotic regimens, the bisphosphonates are efi-
cacious and more evident for the prevention of osteoporotic fracture, for 
reducing the incidence of osteoporotic vertebral fractures, and for sup-
porting improvements in BMD values in postmenopausal women with 
osteopenia or osteoporosis without fracture. Additional evidence is 
necessary to strengthen the eficacy of non-bisphosphonate regimens in 
the prevention of osteoporotic fractures in postmenopausal women with 
osteopenia or osteoporosis without fracture. 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.bonr.2020.100729. 
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